Vistra Corp. (NYSE:VST) (the “Company” or “Vistra”) announced today the pricing of upsized private offerings of $400 million aggregate principal amount of 6.950% senior secured notes due 2033, which form a part of the same series of the Issuer’s (as defined below) outstanding 6.950% Senior Secured Notes due 2033 issued on September 26, 2023, at a price to the public of 102.177% of their face value (the “Secured Notes”) in a private offering (the “Secured Offering”) and $350 million aggregate principal amount of 7.750% senior unsecured notes due 2031, which form a part of the same series of the Issuer’s outstanding 7.750% Senior Notes due 2031 issued on September 26, 2023, at a price to the public of 102.00% of their face value (the “Unsecured Notes” and, together with the Secured Notes, the “New Notes”) in a concurrent private offering
What’s Going On With Bio-Path Stock?
Bio-Path Holdings shares are trading higher Monday after the company announced the presentation of interim results from its Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML).
